E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors.
Hum Gene Ther
; 12(3): 219-26, 2001 Feb 10.
Article
in En
| MEDLINE
| ID: mdl-11177559
ABSTRACT
Clinical studies were performed with a recombinant mutant adenovirus with an E1B 55-kDa deletion, dl1520, to assess its toxicity and efficacy in patients with irresectable primary and secondary liver tumors. A phase I study showed that dl1520 was well tolerated when administered directly intratumorally, intraarterially, or intravenously up to a dose of 3 x 10(11) PFU. Ultrastructural examination of tissue showed the presence of adenovirus in cell cytoplasm around the nucleus and revealed two dissimilar end points of cell death after virus infection a preapoptotic sequence and necrosis. A phase II study showed that the combination of dl1520 and 5-fluorouracil (5-FU), when infused into the hepatic artery, was well tolerated. Further improvement in the recombinant vector design will be needed in order to achieve better clinical response.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Genetic Therapy
/
Adenoviridae
/
Adenovirus E1B Proteins
/
Liver Neoplasms
Type of study:
Clinical_trials
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Hum Gene Ther
Journal subject:
GENETICA MEDICA
/
TERAPEUTICA
Year:
2001
Document type:
Article
Affiliation country:
United kingdom